MindRank Advances AI-Engineered Oral GLP-1 Candidate MDR-001 into Pivotal Phase III Trial
Hangzhou-based MindRank has launched the Phase III “MOBILE” trial for MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist targeting chronic…
Hangzhou-based MindRank has launched the Phase III “MOBILE” trial for MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist targeting chronic…